These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 14660806)

  • 41. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
    Simon A; Warszawski J; Kariyawasam D; Le Chenadec J; Benhammou V; Czernichow P; Foissac F; Laborde K; Tréluyer JM; Firtion G; Layouni I; Munzer M; Bavoux F; Polak M; Blanche S;
    JAMA; 2011 Jul; 306(1):70-8. PubMed ID: 21730243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
    Podzamczer D; King MS; Klein CE; Flexner C; Katlama C; Havlir DV; Letendre SL; Eron JJ; Brun SC; Bernstein B
    HIV Clin Trials; 2007; 8(4):193-204. PubMed ID: 17720659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
    J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
    Chrysos G; Mikros S; Kokkoris S; Pastelli A; Kontochristopoulos G
    J Drugs Dermatol; 2007 Jul; 6(7):742-3. PubMed ID: 17763601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
    Sprinz E; Neto AJ; Bargman E; Green SL; Luo MP; Sylte JR; McMillan FI; King KR; Rode RA; Brun SC; Hanna GJ; Podsadecki TJ
    HIV Clin Trials; 2006; 7(6):291-308. PubMed ID: 17197377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
    HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone.
    Rouanet I; Peyrière H; Mauboussin JM; Vincent D
    HIV Med; 2003 Apr; 4(2):149-50. PubMed ID: 12702137
    [No Abstract]   [Full Text] [Related]  

  • 54. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.
    Arabi YM; Asiri AY; Assiri AM; Balkhy HH; Al Bshabshe A; Al Jeraisy M; Mandourah Y; Azzam MHA; Bin Eshaq AM; Al Johani S; Al Harbi S; Jokhdar HAA; Deeb AM; Memish ZA; Jose J; Ghazal S; Al Faraj S; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; Al-Hameed F; Al Saedi A; Alharbi NK; Fowler RA; Hayden FG; Al-Dawood A; Abdelzaher M; Bajhmom W; AlMutairi BM; Hussein MA; Alothman A;
    N Engl J Med; 2020 Oct; 383(17):1645-1656. PubMed ID: 33026741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
    Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD;
    Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
    AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.
    Loutfy M; Raboud J; Thompson C; Tseng A; Abdurrahman Z; Kovacs C; Rachlis A; Phillips E; Rubin G; Gough K; Walmsley S
    HIV Clin Trials; 2003; 4(5):301-10. PubMed ID: 14583846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
    Nelson M; Girard PM; Demasi R; Chen L; Smets E; Sekar V; Lavreys L
    J Antimicrob Chemother; 2010 Jul; 65(7):1505-9. PubMed ID: 20498120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
    Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C
    HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.